Drug Trial Radar · NCT07938411
A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Oct 22, 2030
Study completion Oct 22, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to demonstrate the superiority of pacibekitug compared to placebo in reducing the risk of 3-point coronary major adverse cardiovascular events (3P-Coronary- MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization, in participants after an MI, at high cardiovascular (CV) risk and receiving standard of care (SoC) secondary CV prevention therapies.
Conditions
- Myocardial Infarction
Interventions
PacibekitugDrug
pacibekitug s.c.
PlaceboDrug
Placebo s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence of 3P-Coronary-MACETime frame: Up tp 1398 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.